[Cyclophosphamide therapy of progredient chronic polyarthritis with special reference to acid alpha 1-proteins and immunoglobulins].
D000328:Adult; D000368:Aged; D001172:Arthritis, Rheumatoid / Q000188:drug therapy* / Q000276:immunology; D001799:Blood Sedimentation; D003520:Cyclophosphamide / Q000009:adverse effects / Q000627:therapeutic use*; D003967:Diarrhea / Q000209:etiology; D005260:Female; D006023:Glycoproteins / Q000097:blood*; D006801:Humans; D007074:Immunoglobulin G / Q000032:analysis; D007075:Immunoglobulin M / Q000032:analysis; D007136:Immunoglobulins / Q000032:analysis; D007239:Infections / Q000209:etiology; D007970:Leukopenia / Q000209:etiology; D008297:Male; D008875:Middle Aged; D009325:Nausea / Q000209:etiology; D014839:Vomiting / Q000209:etiology; D005719:gamma-Globulins / Q000032:analysis*
D006023:Glycoproteins; D007074:Immunoglobulin G; D007075:Immunoglobulin M; D007136:Immunoglobulins; D005719:gamma-Globulins; D003520:Cyclophosphamide
Cyclophosphamid-Behandlung der progredient-chronischen Polyarthritis unter besonderer Berücksichtigung des sauren alpha 1-Glykoproteins und der Immunglobuline.